Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Nov

Today In Oncology

Opening Session Panel Discussion

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC

Pediatric Brain Tumors Prognostic AI Model Guides Precision Therapy Choices

Osimertinib Plus Savolitinib in EGFR-Mutated NSCLC After Disease Progression

Optimizing Treatment for Relapsed/Refractory Follicular Lymphoma

A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery